Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Eberhard Karls University of Tübingen's messenger RNA drug developer CureVac priced the offering at the top of its range.

GlaxoSmithKline Eli Lilly and Genmab-backed messenger RNA drug developer CureVac priced the offering at the top of its range.

The fungal disease drug developer pulled in $60.8m from investors including Novo, which is switching board members at the company.

Carillon Clinics and Maccabi Healthcare Service have contributed to the $150m raised by the medical technology fund as anchor investors.

The healthcare automation software developer has now raised $70m altogether, with Optum Ventures leading its latest round.

Optum Ventures and Echo Health Ventures helped the healthcare chatbot provider take its overall funding to more than $41m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Vision Medicals secured follow-on funding from Cash Capital in a round that brought the precision diagnostic tool developer's total to $42.8m.

University of Utah's biotech incubator has admitted its first three residents taking aim at cancer, liver fibrosis and eosinophil-related diseases.